Suchergebnisse - "Inotai, Andras"

PubPharm (170)

1

Learnings from cross-border biosimilar pricing policies in Europe

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2024

von Simoens, S. | Lacosta, T. | Inotai, A.

2

Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024

von McQueen, R. | Inotai, A. | Zemplenyi, A. | +3

3

A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars : An ISPOR Special Interest Group Report

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2023

von Moorkens, E. | Lacosta, T. | Dawoud, D. | +7

4

Framework for Patient Experience Value Elements in Rare Disease : A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods

enthalten in: PharmacoEconomics - open | 2023

von McQueen, R. | Mendola, N. | Jakab, I. | +5

5

Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe : Findings and Implications"

enthalten in: BioMed research international | 2023

von Godman, B. | Wladysiuk, M. | McTaggart, S. | +41

ErratumFor: Biomed Res Int. 2021 Oct 11;2021:9996193. - PMID 34676266

6

Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods

enthalten in: PharmacoEconomics - open | 2022

von McQueen, R. | Mendola, N. | Jakab, I. | +5

7

Access to high-priced medicines in lower-income countries in the WHO European Region

Erschienen: Copenhagen, Denmark, World Health Organization, [2022]

Oslo medicines initiative technical report

von Németh, B. | Csanádi, M. | Inotai, A. | +2

8

Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer

enthalten in: Cancer treatment reviews | 2021

von Inotai, A. | Ágh, T. | Maris, R. | +4

9

Development of a core evaluation framework of value-added medicines : report 1 on methodology and findings

enthalten in: Cost effectiveness and resource allocation : C/E | 2021

von Petykó, Z. | Kaló, Z. | Espin, J. | +5

10

Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings

enthalten in: Cost effectiveness and resource allocation | 2021

von Petykó, Z. | Kaló, Z. | Espin, J. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]